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Abstract
Purpose Cluster of differentiation 93 (CD93) is involved in
apoptosis and inflammation and has a suggested role in angio-
genesis, and all of which are involved in the development and
dissemination of cancer.We evaluated the expression of CD93
and the association with two single nucleotide polymorphisms
(SNPs), rs2749812 and rs2749817, as possible biomarkers in
colorectal cancer (CRC).
Methods Tissue levels and plasma levels of CD93 were mea-
sured using an enzyme-linked immunosorbent assay (ELISA).
Expression of CD93 was determined by immunohistochemis-
try, western blot and gene expression analysis. Genotype fre-
quencies were established for the SNPs by real-time polymer-
ase chain reaction (PCR), and the association with tumour
stage and survival was analysed.
Results Total CD93 levels were 82 % higher (P<0.001) in
tumours compared to matched normal tissues. Mean levels
of soluble CD93 in plasma were 30 % lower (P<0.001) in
the patients compared to the controls. The T/T genotype of
SNP rs2749817 was more common in stage IV patients, with
consequently higher risk of CRC death (T/T vs. C/C and C/T;
hazard ratio (HR)=1.73, 95% confidence interval (CI)=1.11–
2.67, P=0.014), and was associated with a higher risk of CRC
recurrence after radical operation (T/T vs. C/C and C/T; HR=
2.07, CI=1.22–3.51, P=0.007).
Conclusions We showed that the T/T genotype of SNP
rs2749817 is associated with disseminated cancer at diagnosis
and an increased recurrence rate after radical operation. Pa-
tients with this genotypemay benefit from early identification.
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Introduction
Colorectal cancer (CRC) is the fourth most common cause of
cancer mortality worldwide [1]. Local immunoregulation me-
diated by infiltration of inflammatory cells into colorectal ad-
enocarcinomas and the development of chronic inflammation
is considered of importance for tumour progression [2]. There
is a need of predictive and prognostic factors in CRC. Risk
factors in stages II and III have been of particular interest to
tailor adjuvant treatment for the individual patient and to min-
imize the risk of toxicity [3, 4]. In CRC therapy, Kirsten RAS
(KRAS) mutation status is a predictive marker for non-
response to epidermal growth factor receptor (EGFR)-targeted
drugs and is currently the only biomarker used for the man-
agement of CRC [5]. It has also been suggested that inherited
genetic variations in immune-related genes, such as interleu-
kin (IL)-4 and IL-6, may be associated with prognosis in CRC
[6]. Although several biomarkers have been suggested for
follow-up of treated CRC patients, their clinical application
has not yet been fully evaluated [5, 7–9].
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Human cluster of differentiation 93 (CD93) is an epidermal
growth factor (EGF)-like domain containing transmembrane
protein [10–12], which appears in two forms; a cell-associated
full-length form and a truncated soluble form [13]. Expression
of CD93 is seen on a variety of cell types involved in the
inflammatory cascade and haematopoiesis [14, 15] and is pre-
dominantly expressed in the vascular endothelium [10]. Gene
expression of CD93 has also been suggested to play a role in
adhesion, phagocytosis and angiogenesis [10, 14–16]. Release
and production of soluble CD93 also seems to be mediated by
matrix metalloproteinases (MMPs) [17], but even proinflam-
matory cytokines such as tumor necrosis factor (TNF)-α has
been proven to induce shedding of CD93 [10]. A correlation
between a single nucleotide polymorphism (SNP) of CD93,
rs2749812, and the risk of myocardial infarction (MI) and
coronary heart disease (CHD) has been reported [18–20],
and a reduced expression of soluble CD93 in plasma has been
suggested as a potential biomarker for MI among Swedish
patients with coronary artery disease (CAD) [20]. Recently,
another study showed higher soluble levels of CD93 among
Korean patients with acute MI, and they concluded that circu-
lating CD93 might be a marker of monocyte inflammation in
these patients [21]. These different results might be depended
on the study design and ethnical differences. In an American
study, high expression of CD93 was associated with higher
survival rate among patients with multiple myeloma (MM)
treated with bortezomib, indicating that high levels of CD93
may be a possible marker for better outcome in these patients
[22]. Also, an association between SNP, rs2749817, of CD93
and the risk of breast cancer among Korean women has pre-
viously been described [23].
The aim of this study was to evaluate the expression of
CD93 and the two SNPs of CD93 (rs2749812 and
rs2749817) as possible candidate biomarkers of CRC.
Patients and methods
Study population
This study involved analysis of tissue sections, tissue lysates,
plasma, ribonucleic acid (RNA) and deoxyribonucleic acid
(DNA) samples fromCRC patients from southeastern Sweden
who had undergone surgical resections for primary colorectal
adenocarcinomas at the Department of Surgery, County Hos-
pital Ryhov, Jönköping, Sweden, during 1996 through 2012.
The clinicopathological characteristics of the patients were
obtained from surgical and pathological records. Follow-up
was made through the medical records from all hospital de-
partments and the primary care up to December 31, 2013. The
date of an eventual recurrence and the date and cause of death
as related to colorectal cancer or not were determined from a
review of the patient’s files.
The patient group comprised 370 patients, including 197
males and 173 females with a mean age of 70 years (range 25–
93). The control group comprised 316 blood donors, including
188 males and 128 females, with no known CRC history and
from the same geographical region as the patients with a mean
age of 61 years (range 41–70). The study was approved by the
Local Ethics Committee of Linköping University, Sweden
(Dnr. 2013/271-31), and informed consent was obtained from
each patient.
Tissue samples
Tumour and matched normal tissue samples were analysed
from 101 of the 370 patients. The 101 patients consisted of
59 males and 42 females with a mean age of 70 years (range
36–90) with a tumour localized in the colon (n=58) or rectum
(n=43). The tumours were classified according to the Amer-
ican Joint Committee on Cancer (AJCC) classification sys-
tem; stage I (n=17), stage II (n=30), stage III (n=34) and
stage IV (n=20). During surgery, tumour tissue and adjacent
normal mucosa (~5 cm from the tumour) were excised from
each patient and immediately frozen at −70 °C until analysis.
Frozen normal and tumour tissue were thawed and homoge-
nized in an ice-cold lysis buffer as previously described [24].
The protein content of the lysate supernatant fluid was deter-
mined using the Bradford protein assay (Bio-Rad Laborato-
ries, Ltd., Hertfordshire, UK).
Plasma samples
Venous blood samples were collected during surgery and cen-
trifuged within 1 h to separate plasma and blood cells. Plasma
was stored at −70 °C until analysis. Plasmawas available from
110 patients (60 males and 50 females) with a mean age of
69 years (range 36–90) and from 106 controls (65 males and
41 females) with a mean age of 60 years (range 41–68). The
patient’s tumours were localized in the colon (n=68) or rec-
tum (n=42) and were classified as stage I (n=17), stage II (n=
30), stage III (n=42) and stage IV (n=21).
Western blot
Proteins in both tumour and matched normal tissue lysates
were separated under reducing conditions by electrophoresis
in a Novex 4–12 % Tris-Glycine Gel (Invitrogen/Life Tech-
nologies Ltd., Paisley, UK) using a standard protocol. In brief,
separated proteins were transferred onto polyvinylidene
difluoride (PVDF) transfer membranes (Amersham, Bucking-
hamshire, UK), blocked for 1 h with 5 % (wt/vol) non-fat dry
milk and probed overnight with goat anti-human C1qR1/
CD93 antibody (1 μg/mL; R&D Systems, Inc., MN, USA).
After extensive washing, the blots were re-incubated for 1 h at
room temperature with bovine horseradish peroxidase-
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conjugated anti-goat IgG secondary antibody (0.1 μg/mL;
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blots were
developed using an enhanced chemiluminescence Prime
Western Blotting Detection Reagent system (Amersham).
Immunohistochemistry
CD93 staining was performed using a standard protocol
on 4 μm sections from formalin-fixed paraffin-embedded
tissue blocks as previously described [24]. Sections were
subsequently incubated with a primary goat anti-human
C1qR1/CD93 antibody (0.2 μg/mL; R&D Systems) over-
night at 4 °C and then with a horse secondary biotinylated
affinity-purified anti-goat IgG antibody (1.5 μg/mL; Vec-
tor Laboratories, Ltd., Burlingame, CA, USA). Avidin-
biotin peroxidase complexes (Vector laboratories) were
added followed by visualization with 3.3′-diaminobenzi-
dine (Vector Laboratories). Sections were counterstained
with haematoxylin (Vector laboratories) and rehydrated
before coverslips were added. Microscopy of the sections
was performed using a Zeiss light microscope (Carl Zeiss
Microscopy GmbH, Göttingen, Germany) along with the
Zen lite software (Zeiss).
Quantification of CD93 in tissue lysates and plasma
CD93 was measured in tissue lysates and plasma using a
commercial enzyme-linked immunosorbent assay (ELISA)
kit (R&D Systems Europe, Ltd., UK) and performed as pre-
viously described [20]. Tissue levels and plasma levels were
determined using the Sunrise TecanMicroplate Reader (Tecan
Austria GmbH, Salzburg, Austria) along with the Magellan
7.x 2010 software (Tecan). Tissue levels of CD93 in lysates
were expressed as nanogram per milligram (ng/mg) of total
CD93 and plasma levels of soluble CD93 as nanogram per
millilitre (ng/mL).
RNA extraction, cDNA synthesis and RNA quantification
Total RNA from 14 matched tumour and normal tissue biop-
sies was isolated using the RNeasy kit (Qiagen, Hilden, Ger-
many). Complementary DNA (cDNA) amplification and real-
time polymerase chain reaction (PCR) analysis were per-
formed as previously described [25]. The CD93 (Life Tech-
nologies) expression results were normalized to the values of
human glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), large ribosomal protein (RPLP0) and TATA-
binding protein (TBP) (Life Technologies).
DNA extraction and genotype determination
Whole blood DNAwas extracted from 356 patients and from
305 controls for analysis of the SNPs rs2749817 and
rs2749812. DNAwas extracted using a QiaAmp DNA blood
kit (Qiagen), and a TaqMan SNP genotyping assay was used
for the analysis of rs2749812 and rs2749817 genotypes (Ap-
plied Biosystems/Life Technologies). DNA (10 ng) was
mixed with TaqMan Universal PCR Master mix II (Applied
Biosystems) and amplified using the 7500 Fast Real-Time
PCR system (Applied Biosystems). All the patients were
available with registered follow-up regarding survival, stadi-
um (stage I=64, stage II=130, stage III=108 and stage IV=
54) and localization (colon=189 and rectum=167).
Statistical analysis
Differences in the frequencies of the CD93 SNPs between
patients and controls and the association with localization
and stage of the tumour were analysed by the chi-squared test.
The Hardy-Weinberg equilibrium was tested for the geno-
types. Differences in CD93 expression between tumour and
matched normal tissues were examined by the Wilcoxon’s
signed rank test, while differences in plasma CD93 levels
between patients and controls were tested by the Mann-
Whitney U test. These analyses were performed using the
SPSS for Windows computer package (IBM SPSS Statistics,
2012, version 19, SPSS Inc., Chicago, IL, USA). Cancer-
specific and disease-free survival analysis was performed by
Cox’s regression and Kaplan-Meier analysis with the log-rank
test, using the STATA 12 software (StataCorp, 2009, Stata
Statistical Software: Release 12, College Station, TX, USA).
The results were considered as statistically significant at
P<0.05.
Results
Localization and expression of CD93 in tumour
and normal tissue
Expression of CD93 was predominantly seen in endothelial
cells around blood vessels in cancerous tissue (Fig. 1a, b).
CD93 was less expressed in normal tissue, and only weak
staining was observed in some vascular endothelial cells
(Fig. 1c). No difference in gene expression of CD93was noted
between matched normal or cancerous tissue (data not
shown). Western blot analysis revealed a heterogeneous ex-
pression of CD93 in both normal and cancerous tissue, with
two bands representing full length and truncated forms of
CD93. The proteins had an approximate size of 75 and
110 kDa (Fig. 2). Quantification of total CD93 in the tissue
lysates, using ELISA, showed a significantly 82 % higher
expression in tumour tissues (mean, 7.1; standard deviation
(SD), 3.33 ng/mg) compared to matched normal tissues
(mean, 3.9; SD, 2.04 ng/mg) (P<0.001) (Fig. 3). Eighty-
nine out of the 101 patients had a significantly (P<0.001)
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higher expression of CD93 in tumour tissue compared to
matched normal tissue. The expression of total CD93 was
not associated with stage, localization, gender or age (data
not shown).
Levels of CD93 in plasma
The level of the soluble form of CD93 in plasma was signif-
icantly 30 % lower in the CRC patients (mean, 129.7; SD,
55.74 ng/mL) compared to the controls (mean, 186.0; SD,
74.47 ng/mL) (P<0.001) (Fig. 4). No association was seen
between level of soluble CD93 and stage, localization, gender
or age (data not shown).
Genotype frequencies and survival estimates
Genotype frequencies of SNP rs2749817 did not differ
between the patients and controls (Table 1). Overall distri-
bution of genotypes based on location and stage is de-
scribed in Table 2. The distribution of the genotypes of
SNP rs2749817 showed an increased frequency of the T/
T genotype in stage IV (P=0.009) when compared to stage
I–III. No association between tumour site and the genotype
distribution of SNP rs2749817 was seen (Table 2). The
cancer specific survival differed between the genotypes
of SNP rs2749817 (Fig. 5, log-rank test, P=0.013). The
T/T genotype had the highest risk of CRC death with aC
A
B
Fig. 1 Immunohistochemical staining of CD93 in humanCRC (a, b) and
normal tissue (c). In tumour tissue, CD93 is present in endothelial cells
located around small (a) and large blood vessels (b). In normal tissue,
only faint CD93 expression in some vascular endothelial cells located
around blood vessels is seen (c), scale bar=20 μm
N     T     N      T    N      T     N       T
~110 kDa
~75 kDa
Fig. 2 Western blot analysis of CD93 protein expression (~75 and
~110 kDa) in four representative specimens of human colorectal tumour






















Fig. 3 Tissue expression of total CD93 (ng/mg) from tumour and
matched normal tissues in 101 CRC patients examined by ELISA;
asterisks indicate P<0.001
886 Int J Colorectal Dis (2015) 30:883–890
hazard ratio (HR) of 1.73 (95 % confidence interval (CI)=
1.11–2.67, P=0.014) compared with the genotype C/C and
C/T (Table 3). In patients that were tumour-free after op-
eration (stage I–III and R0 resection), the T/T genotype
had a worse prognosis, with a lower recurrence-free sur-
vival compared to patients with C/C and C/T genotype
(Fig. 6, log-rank test, P=0.047) and an increased risk of
recurrence in CRC (Table 4, HR=2.07, CI=1.22–3.51, P=
0.007). When comparing the genotype frequencies of SNP
rs2749817 to tissue levels of total CD93, the tumour tissue
levels were significantly higher (20 %) among patients
with T/T genotype (mean, 8.3; SD, 3.10 ng/mg) compared
with C/C and C/T genotypes (mean, 6.9; SD, 3.36 ng/mg)
(P=0.037). There was no association in normal tissue
levels (data not shown). We also examined the genotypes
of SNP rs2749812, but no difference in genotype frequen-
cies between patients and controls was observed. Among
the patients, no association with stage and levels of CD93
was shown, and the genotypes of SNP rs2749812 did not
have any effect on the survival of the CRC patients (data
not shown).
Adjustment for localization, gender and age did not signif-
icantly affect these results for either of the SNPs.
Discussion
New prognostic markers in CRC can help us to better under-
stand the disease and to predict prognosis and can also serve as
a basis for individualized therapy. In the present study, we
found that (i) CD93 was increased and expressed in endothe-
lial cells in blood vessels in CRC tissue; (ii) the plasma level
of CD93 was lower in the CRC patients compared with the
controls; (iii) the T/T genotype of rs2749817, a CD93-related
SNP, was associated with disseminated cancer and an in-
creased recurrence rate in patients that had the entire tumour
removed at operation, which correlated to higher CD93 levels
in the cancer.
During cancer development and progression, elevated in-
flammation is observed in cancer tissue due to the infiltration
of leukocytes [26] and increased expression of proinflamma-
tory cytokines. Also, chronic inflammation plays an important
role as a risk factor in CRC [27]. CD93 is expressed on and
shed from cells involved in the inflammatory cascade [28],
and the release and production of soluble CD93 is enhanced























Fig. 4 Plasma expression of soluble CD93 (ng/mL) from 110 CRC









C/C 114 (32.0) 97 (31.8)
C/T 176 (49.4) 165 (54.1)
T/T 66 (18.6) 43 (14.1)
*Patients vs. controls is non-significant
Table 2 Genotype distribution of SNP rs2749817 in numbers (%) in
356 CRC patients in relation to tumour site and stage
Genotypes Patients C/C C/T T/T
*Tumour site
Colon 189 62 (54.4) 93 (52.8) 34 (51.5)
Rectum 167 52 (45.6) 83 (47.2) 32 (48.5)
**Stage
I 64 23 (35.9) 32 (50.0) 9 (14.1)
II 130 41 (31.5) 71 (54.6) 18 (13.9)
III 108 37 (34.3) 50 (46.3) 21 (19.4)
IV 54 13 (24.1) 23 (42.6) 18 (33.3)
*Tumour site is non-significant; **stage overall,P=0.070; stages I–III vs.
IV, P=0.009
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Fig. 5 Kaplan-Meier curve describing cancer-specific survival estimates
among CRC patients according to C/C (middle blue line), C/T (upper red
line) and T/T (lower green line) genotypes of SNP rs2749817; P=0.013
Int J Colorectal Dis (2015) 30:883–890 887
protein has a role in innate immunity and above all in apopto-
sis and inflammation [11, 30–33]. In our study, an increased
expression of CD93 was observed in CRC tissue in the endo-
thelial cells of blood vessels, while CD93 was found to a
limited extent in blood vessels in normal tissue. Increased
CD93 expression in endothelial cells could be involved in
the response to local inflammation and on-going angiogenesis
within the tumour. The involvement of CD93 in angiogenesis
has previously been suggested in developing mice embryos
[14], and the EGF-like domain of CD93 has been shown to
stimulate angiogenesis in vitro in human umbilical vein endo-
thelial cells (HUVEC) [10].
In our study, the levels of CD93 in plasma in the CRC
patients were significantly lower compared to the controls.
A low level of CD93 in plasma is surprising since CD93 is
cleaved by MMPs and released, and MMPs are found in
higher levels in CRC [17]. The low CD93 levels could indi-
cate that only a small amount of CD93 is released from the
tumour into the circulating blood of CRC patients due to un-
known mechanisms or that the patients have an immunologic
imbalance resulting in impaired production of CD93 from
leucocyte and endothelial cells and/or restricts the secretion
of CD93 from epithelial cells in colon and rectum. However,
low CD93 levels in plasma have previously been found in
patients with MI, a disease also involving an increased inflam-
matory response and MMPs [20]. The majority of the CRC
patients (65.5 %) had soluble CD93 levels lower than 142 ng/
mL, a threshold which was previously associated with
increased risk for MI among a Swedish patient population
with CAD [20]. Whether the low plasma levels of CD93 in
patients is a significant level for both risk for cardiovascular
diseases and CRC, or whether it reflects similar physiological
and pathological mechanisms in the regulation of CD93 need
to be further investigated.
The development of molecular markers has started to show
promising results, but only KRAS mutation status has been
accepted as a predictive marker for CRC and the response to
drug treatment [5]. Different genes and SNPs have been cor-
related with clinical stage, presence of lymph node metastasis,
clinical outcome, increased survival, follow-up after treatment
and the risk of recurrence in CRC patients. These markers may
be used as a supplement to the tumour lymph nodes metastasis
(TNM) staging system, which alone cannot predict cancer
prognosis [34–36].
We investigated the genotype distribution of two SNPs of
the CD93 gene to see whether they were of any clinical im-
portance in CRC. We showed that the T/T genotype of SNP
rs2749817 is associated with disseminated cancer at diagnosis
and increased risk of recurrence after radical operation, sug-
gesting a lower resistance to the dissemination of tumour cells
and reduced ability to control metastasis. No association be-
tween plasma CD93 levels and the genotypes of SNP
rs2749817 in patients or controls was seen. However, this
SNP has previously been studied among Korean women,
and it was shown to have a correlation with breast cancer risk
[23]. Hence, our results indicate that the T/T genotype of SNP
rs2749817 may be used as a marker related to severe tumour
disease and spread, even at the time of diagnosis, and may
therefore be considered as a potential biomarker for outcome
and survival in CRC. The exact mechanism of the T/T geno-
type is currently not known, but it is associated with increased
tissue level of CD93 in the cancer that might affect angiogen-
esis, growth and spreading. The SNP rs2749817 is situated
downstream of the 3′untranslated region (UTR) of the CD93
gene which could potentially affect translation and post trans-
lational modifications of the gene. The exact role of SNP
rs2749817 on CRC survival remains unknown, but the data
identifies the SNP as a risk marker for this variable.
Our data implies that identifying individuals with the T/T
genotype at an early stage could be of importance both for
outcome, follow-up and individualized treatment for CRC pa-
tients. Even though lower plasma levels of CD93 are found in
both CRC and CAD patients, SNP rs2749817 is not
Fig. 6 Kaplan-Meier curve describing disease-free survival estimates
among CRC patients in stage I–III after R0 resection according to C/C
(middle blue line), C/T (upper red line) and T/T (lower green line) geno-
types of SNP rs2749817; P=0.047
Table 4 Disease-free survival in CRC patients in stage I–III
Genotypes HR 95 % CI P value
T/T vs. C/C 2.02 1.06–3.85 0.034
T/T vs. C/T 2.12 1.19–3.76 0.010
T/T vs. C/C and C/T 2.07 1.22–3.51 0.007
Table 3 Cancer specific mortality in CRC patients in stage I–IV
Genotypes HR 95 % CI P value
T/T vs. C/C 1.48 0.89–2.47 0.132
T/T vs. C/T 1.93 1.20–3.12 0.008
T/T vs. C/C and C/T 1.73 1.11–2.67 0.014
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associated with CAD, which indicates that this SNP will not
be influenced by CAD [20].
The present study shows significantly higher CD93 levels
in cancerous compared to matched normal tissues. Our obser-
vations also suggest that a low plasma concentration of CD93
may be a novel biomarker for CRC, but this must be further
evaluated to be able to reveal the biological mechanism of
plasma CD93 in CRC patients. Most importantly, a genotype
belonging to an SNP of CD93 is correlated with disseminated
CRC and may predict outcome for CRC patients.
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